PDF(Pubmed)
Abstract：
Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker used clinically to support the diagnosis and recurrence of pancreatic adenocarcinoma. CA 19-9 levels may be found to be elevated too in benign conditions, including hepatobiliary diseases such as choledocholithiasis, cholangitis, or cholestasis of any etiology. In this case, we are presenting a case of a 66-year-old man who has presented with diffuse abdominal pain and has been then found to have choledocholithiasis and obstructive jaundice treated with biliary sphincterotomy and balloon extraction. In the setting of extensive unclear gastroenterological surgeries, tumor markers were obtained, and the results revealed markedly elevated CA 19-9 with negative other tumor markers and a negative workup for malignancy. After reviewing the literature, we found that although CA 19-9 has been studied in diagnosing pancreatic and biliary malignancies, the serum level may also be elevated in many other benign conditions. As a result, the results must be individualized according to the clinical scenario of each patient.
摘要：
糖类抗原19-9(CA19-9)是临床上用于支持胰腺腺癌的诊断和复发的肿瘤标志物。CA19-9水平在良性条件下也可能被发现升高，包括胆总管结石等肝胆疾病，胆管炎,或任何病因的胆汁淤积。在这种情况下,我们介绍一例66岁男性患者,他出现了弥漫性腹痛,随后发现患有胆总管结石和梗阻性黄疸,采用胆道括约肌切开术和球囊拔除术治疗.在广泛的不清楚的胃肠手术中，获得肿瘤标志物，结果显示CA19-9明显升高，其他肿瘤标志物阴性，恶性肿瘤检查阴性。在回顾了文献之后，我们发现，虽然CA19-9已被用于诊断胰腺和胆道恶性肿瘤，在许多其他良性疾病中，血清水平也可能升高。因此,结果必须根据每位患者的临床情况进行个体化.
